GL

GlycoMimetics

- NASDAQ:GLYC
Last Updated 2024-04-16

LinkedIn Profile

Access GlycoMimetics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:glyc 819274 Apr 14th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 13th, 2024 11:06PM Apr 14th, 2024 11:05AM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 13th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 12th, 2024 10:57PM Apr 13th, 2024 11:32AM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 12th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 11th, 2024 11:02PM Apr 12th, 2024 08:27AM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 11th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 10th, 2024 11:35PM Apr 11th, 2024 11:12AM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 10th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 9th, 2024 11:05PM Apr 10th, 2024 05:20PM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 9th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 8th, 2024 11:16PM Apr 9th, 2024 10:01AM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 8th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 7th, 2024 11:41PM Apr 8th, 2024 06:59PM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 7th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 6th, 2024 11:12PM Apr 6th, 2024 11:12PM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 6th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 5th, 2024 11:12PM Apr 5th, 2024 11:12PM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology
nasdaq:glyc 819274 Apr 5th, 2024 12:00AM GlycoMimetics 3.6K 50.00 Open Apr 4th, 2024 11:39PM Apr 4th, 2024 11:39PM At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC. Open small molecule drugs, carbohydrate chemistry, orphan drugs, and biotechnology Open 9708 Medical Center Drive Rockville MD US 20850 GlycoMimetics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.